

Arvin C Dar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7333065/publications.pdf>

Version: 2024-02-01

21
papers

1,426
citations

687335

13
h-index

839512

18
g-index

24
all docs

24
docs citations

24
times ranked

2769
citing authors

#	ARTICLE	IF	CITATIONS
1	The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling. Annual Review of Biochemistry, 2011, 80, 769-795.	11.1	316
2	Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature, 2012, 486, 80-84.	27.8	312
3	A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature, 2011, 472, 366-369.	27.8	223
4	Structural basis for the action of the drug trametinib at KSR-bound MEK. Nature, 2020, 588, 509-514.	27.8	86
5	Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation. Chemistry and Biology, 2008, 15, 1015-1022.	6.0	84
6	Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. Nature, 2016, 537, 112-116.	27.8	74
7	Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors. Nature Communications, 2014, 5, 5408.	12.8	66
8	A whole-animal platform to advance a clinical kinase inhibitor into new disease space. Nature Chemical Biology, 2018, 14, 291-298.	8.0	56
9	Endoplasmic reticulum stress-independent activation of unfolded protein response kinases by a small molecule ATP-mimic. ELife, 2015, 4, .	6.0	49
10	Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR. Nature Biotechnology, 2022, 40, 1680-1689.	17.5	29
11	A pickup in pseudokinase activity. Biochemical Society Transactions, 2013, 41, 987-994.	3.4	16
12	Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. Molecular Cancer Therapeutics, 2019, 18, 1506-1519.	4.1	16
13	Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability*. Molecular and Cellular Proteomics, 2019, 18, 1630-1650.	3.8	14
14	Integrated computational and Drosophila cancer model platform captures previously unappreciated chemicals perturbing a kinase network. PLoS Computational Biology, 2019, 15, e1006878.	3.2	10
15	Type II Binders Targeting the α -GLR-Out Conformation of the Pseudokinase STRAD \pm . Biochemistry, 2021, 60, 289-302.	2.5	6
16	Ploidy Leads a Molecular Motor to Walk Different Paths to Drug Resistance. Cell Chemical Biology, 2020, 27, 770-772.	5.2	2
17	Understanding and drugging RAS: 40 years to break the tip of the iceberg. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	1
18	Conformational control and regulation of the pseudokinase KSR via small molecule binding interactions. Methods in Enzymology, 2022, 667, 365-402.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Targeting drug-resistant mutations in ALK. Nature Cancer, 2022, 3, 659-661.	13.2	1
20	Structural Insights into How Protein-Protein Interaction Modulates the Action of MEK Inhibitors. Microscopy and Microanalysis, 2021, 27, 1716-1718.	0.4	0
21	An Antagonist of KSR1-Driven Adaptive Resistance to Clinical RAS-MAPK Inhibitors. FASEB Journal, 2022, 36, .	0.5	0